Walleye Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Walleye Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.38M	Sell	4,800 -700	-13%	-$310K	0.01%	1370
2026 Q1	$2.46M	Sell	5,500 -2,400	-30%	-$1.12M	0.01%	1302
2025 Q4	$3.58M	Buy	7,900 +1,100	+16%	+$474K	0.01%	1404
2025 Q3	$2.66M	Sell	6,800 -5,900	-46%	-$2.47M	0.01%	1369
2025 Q2	$5.65M	Sell	12,700 -1,300	-9%	-$599K	0.02%	801
2025 Q1	$6.79M	Buy	14,000 +6,900	+97%	+$3.22M	0.03%	626
2024 Q4	$2.86M	Sell	7,100 -10,600	-60%	-$4.91M	0.01%	1457
2024 Q3	$8.23M	Buy	17,700 +1,900	+12%	+$913K	0.02%	816
2024 Q2	$7.41M	Sell	15,800 -15,200	-49%	-$6.6M	0.01%	976
2024 Q1	$13M	Buy	31,000 +27,300	+738%	+$11.5M	0.02%	669
2023 Q4	$1.51M	Sell	3,700 -3,800	-51%	-$1.4M	﹤0.01%	2010
2023 Q3	$2.61M	Hold	7,500	–	–	0.01%	1524
2023 Q2	$2.64M	Sell	7,500 -900	-11%	-$303K	0.01%	1142
2023 Q1	$2.65M	Buy	8,400 +2,100	+33%	+$630K	0.04%	563
2022 Q4	$1.82M	Buy	6,300 +4,900	+350%	+$1.49M	0.03%	637
2022 Q3	$405K	Buy	+1,400	New	+$403K	0.01%	1615
2020 Q1	–	Sell	-31,100	Closed	-$6.81M	–	1726
2019 Q4	$6.81M	Sell	31,100 -57,500	-65%	-$11.6M	0.44%	22
2019 Q3	$15M	Buy	88,600 +61,200	+223%	+$10.8M	0.89%	3
2019 Q2	$5.03M	Buy	27,400 +17,100	+166%	+$2.99M	0.55%	12
2019 Q1	$1.9M	Buy	+10,300	New	+$1.9M	0.31%	49

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Walleye Capital's VRTX Position: Q2 2026 in Review

Walleye Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 99% in Q2 2026, selling an estimated $13.5M and leaving 335 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #3604.

Walleye Capital first reported a position in VRTX in Q1 2019 and has held it in 27 quarters since. The position peaked at $19.4M in Q3 2022. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Walleye Capital held 335 shares of Vertex Pharmaceuticals worth $166K as of Q2 2026.
Walleye Capital sold 30,417 Vertex Pharmaceuticals shares in Q2 2026, an estimated $13.5M.
Vertex Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3604 holding.
Walleye Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 27 quarters since.
Walleye Capital's Vertex Pharmaceuticals position peaked at $19.4M in Q3 2022.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.